Plain-language explanation.
Neurological disorders are conditions that affect the brain, spinal cord, or nerves. Stroke happens when blood supply to part of the brain is cut off. Alzheimer's disease causes progressive memory loss. Parkinson's disease affects movement. Epilepsy causes seizures. These conditions affect hundreds of millions of people worldwide and are a leading cause of disability.
Core concepts and standard treatment.
Neurological disorders by mechanism: vascular (stroke — ischaemic from thrombosis/embolism, or haemorrhagic; TIA), neurodegenerative (Alzheimer's: amyloid/tau pathology; Parkinson's: alpha-synuclein, dopaminergic nigrostriatal degeneration; ALS: motor neuron loss; Huntington's: CAG repeat expansion), demyelinating (multiple sclerosis: autoimmune attack on myelin), seizure disorders (epilepsy: synchronised abnormal neuronal firing), and infectious/inflammatory (encephalitis, meningitis).
Deeper theory, debates and edge cases.
Stroke is a medical emergency: time is brain — thrombolysis (tPA within 4.5 hours) and mechanical thrombectomy dramatically improve outcomes when delivered rapidly. Neurological rehabilitation exploits neuroplasticity: constraint-induced movement therapy, task-specific practice, and non-invasive brain stimulation (TMS, tDCS) can partially restore function years post-stroke. Anti-amyloid antibodies (lecanemab, donanemab) show modest efficacy in early-stage Alzheimer's disease with significant side effects.
How it is applied in practice.
Neurology faces a global treatment gap: 80% of neurological disease burden is in low- and middle-income countries with severely limited neurology services, diagnostic equipment, and medications. Digital health is transforming neurology: wearable devices monitor movement (Parkinson's tremor, seizure detection via accelerometry), sleep, and activity; teleneurology extends specialist access. Precision neurology — stratifying patients by molecular subtype for targeted treatments — is advancing in epilepsy (genetic testing predicting treatment response) and increasingly in neurodegeneration.